‘Unusual’ Cancers After Pandemic; A Win in TNBC; Shortage Pauses Clinical Trial

Some “unusual” cancers emerged during the pandemic, but is COVID to blame? (Washington Post)

Using routinely collected information about patients with cancer, an artificial intelligence model showed promise for predicting which patients will respond to immune checkpoint inhibitors. (Nature Cancer)

A lower-intensity, three-drug combination, followed by stem cell transplantation (SCT), led to improved relapse-free survival in older patients with acute myeloid leukemia compared with intensive chemotherapy and SCT. (Cancer)

Prenatal care may offer opportunities to gain insight into a mother’s future cancer risk. (Weill Cornell Medicine, American Journal of Obstetrics and Gynecology)

Mutations in the estrogen signaling pathway could provide clues to the origin of lung cancer in never-smokers and to potential new therapies. (Cancer Research)

An investigational screening test for cervical cancer detected significantly more cancers and precancers compared with current screening methods. (Nature Medicine)

A newly discovered protein could provide insight into what drives prostate cancer progression and clues to new treatment approaches. (Molecular Cancer)

The combination of an androgen receptor blocker and chemotherapy led to a 42% response rate in difficult-to-treat triple-negative breast cancer, more than twice as high as historical response rates. (Cell Reports Medicine)

AbbVie announced that its antibody-drug conjugate mirvetuximab soravtansine (Elahere) produced objective responses in 51.9% of women with heavily pretreated, folate receptor alpha-positive, platinum-sensitive ovarian cancer.

Bristol Myers Squibb acknowledged that a radioisotope shortage forced a pause in enrollment for a phase III trial in neuroendocrine tumors. (Endpoints News)

Please enable JavaScript to view the

comments powered by Disqus.